7EY Stock Overview
A clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases in the United States.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 0/6 |
Past Performance | 2/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Kiora Pharmaceuticals, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$3.79 |
52 Week High | US$8.16 |
52 Week Low | US$3.20 |
Beta | -0.22 |
11 Month Change | 0.79% |
3 Month Change | -18.76% |
1 Year Change | -24.86% |
33 Year Change | -99.65% |
5 Year Change | -99.68% |
Change since IPO | -99.97% |
Recent News & Updates
Recent updates
Shareholder Returns
7EY | DE Pharmaceuticals | DE Market | |
---|---|---|---|
7D | 0% | -3.7% | -0.5% |
1Y | -24.9% | -20.5% | 1.6% |
Return vs Industry: 7EY underperformed the German Pharmaceuticals industry which returned -19.7% over the past year.
Return vs Market: 7EY underperformed the German Market which returned 2.4% over the past year.
Price Volatility
7EY volatility | |
---|---|
7EY Average Weekly Movement | 11.6% |
Pharmaceuticals Industry Average Movement | 5.6% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.5% |
10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: 7EY's share price has been volatile over the past 3 months.
Volatility Over Time: 7EY's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1998 | 12 | Brian Strem | www.kiorapharma.com |
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials indicated for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, currently under phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; KIO-101, an eye drop for the treatment of ocular presentation of rheumatoid arthritis; and KIO-201, an eye drop for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair.
Kiora Pharmaceuticals, Inc. Fundamentals Summary
7EY fundamental statistics | |
---|---|
Market cap | €12.04m |
Earnings (TTM) | €2.12m |
Revenue (TTM) | €14.90m |
5.7x
P/E Ratio0.8x
P/S RatioIs 7EY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
7EY income statement (TTM) | |
---|---|
Revenue | US$16.00m |
Cost of Revenue | US$5.08m |
Gross Profit | US$10.92m |
Other Expenses | US$8.64m |
Earnings | US$2.28m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 0.77 |
Gross Margin | 68.23% |
Net Profit Margin | 14.23% |
Debt/Equity Ratio | 0% |
How did 7EY perform over the long term?
See historical performance and comparison